Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 48

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 48
---
 because they
reduce the delivery of harmful agents to normal tissues.

However, while mAb are
more effective than traditional chemotherapy for targeting tumors, there are shortcomings. In particular, their use in molecular
imaging and therapeutics is often impaired by their size resulting in long residence times in the body, associated with slow and low
tumor uptake and with limited tumor penetration potential. Thus, we intend to develop theranostic radiopharmaceuticals that can
provide a more effective diagnosis and treatment of the tumors our clinical products target.

The PSA-mAb technology is
based on a highly selective novel human mAb (PSA-mAb) that identifies prostate specific antigen (“ PSA”) in prostate cancer.
Their use in molecular therapeutics is not impaired by their size, which is less likely to result in long residence times in the body
and slow and low tumor absorption and thus limited penetration. We intend to develop a novel human mAb that is addressing a new target
(KLK3) in the prostate cancer cell, with the potential to deliver a more effective treatment compared to currently available radiopharmaceuticals.

Nanobodies provide an advantage
over mAb in that nanobodies can be radiolabeled with short-lived radioisotopes and provide high contrast images within a few hours after
injection, allowing early diagnosis and reduced radiation exposure of patients. In therapy, the small radioactively labelled nanobodies
show high specificity and a balanced pharmacodynamic profile.

Pivalate and Trivehexin (Avβ6-Integrin)
are small molecules compared to antibodies and consequently may be expected to penetrate a tumor mass. FPIA is recruited by cells as part
of a cancer-relevant biochemical pathway with the consequence that the labelled fluorine moiety in18F-FPIA is absorbed into
tumorous cells. We believe Pivalate has the unique advantage of crossing the blood brain barrier, ending up with significant uptake in
the tumor lesions. Trivehexin is designed to bind to a unique cancer antigen called AvB6. This target is significantly different for integrins
studied for many years that are mainly targeting AvB3 and AvB5.

PTPµ (PTPmu) targeted
agent is a highly specific, targeted agent for the detection, imaging and treatment of tumors. When combined with low level radiation,
the PTPµ-targeted agent functions as a highly specific Positron Emission Tomography (PET) imaging agent. When combined with high